Results 181 to 190 of about 506,903 (380)

The scaffold proteins of lignin biosynthetic cytochrome P450 enzymes

Nature Plants, 2018
Mingyue Gou, Xiuzhi Ran, D. Martin, Chang-Jun Liu   +3 more
semanticscholar   +1 more source

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models

Clinical Pharmacology &Therapeutics, EarlyView.
The use of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety ...
Eunjin Hong, Mary F. Hebert, Emily Fay, Grant Turner, Patricia Eshaghian, Aaron Trimble, Peter S. Chung, Adupa P. Rao, Paul M. Beringer   +8 more
wiley   +1 more source

Mass spectrometry in ocular drug research

Mass Spectrometry Reviews, EarlyView., 2023
Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo, Kati‐Sisko Vellonen, Arto Urtti, Tetsuya Terasaki, Anam Hammid, Paavo Honkakoski, Seppo Auriola   +6 more
wiley   +1 more source

Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone.

, 1992
Scott S. Sundseth, David J. Waxman
openalex   +1 more source

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Autosomal dominant polycystic kidney disease is the most prevalent inherited kidney disease and leads to bilateral kidney enlargement and progressive loss of renal function, often over decades. Comorbidities include hypertension, flank pain, and bacterial infections. The condition often necessitates prolonged multidrug therapy.
Annika C. Tillmann, Dorien J. M. Peters, Amin Rostami‐Hodjegan, Patricia Wilson, Jill Norman, Jill Barber, Zubida M. Al‐Majdoub   +6 more
wiley   +1 more source

Pharmaceutical removal from wastewater by introducing cytochrome P450s into microalgae

Microbial Biotechnology
Pharmaceuticals are of increasing environmental concern as they emerge and accumulate in surface‐ and groundwater systems around the world, endangering the overall health of aquatic ecosystems.
Thamali Kariyawasam, Christian Helvig, Martin Petkovich, Bas Vriens   +3 more
doaj   +1 more source

Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes.

, 1992
Scott S. Sundseth, John A. Alberta, David J. Waxman   +2 more
openalex   +1 more source

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study

Clinical Pharmacology &Therapeutics, EarlyView.
Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent.
Denis Arikci, Friederike Holze, Lorenz Mueller, Patrick Vizeli, Deborah Rudin, Dino Luethi, Cedric M. Hysek, Matthias E. Liechti   +7 more
wiley   +1 more source

Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells

, 1991
Mairéad A. Carroll, Angelo Sala, C. E. Dunn, J C McGiff, R.C. Murphy   +4 more
openalex   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source